Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2018 Feb 6

PMID 29399596

Citations 8

Authors

Max W Adelman

Deborah A McFarland

Mulugeta Tsegaye

Abraham Aseffa

Russell R Kempker

Henry M Blumberg

Affiliations

Soon will be listed here.

Abstract

Background: The World Health Organization (WHO) recommends active tuberculosis (TB) case finding and a rapid molecular diagnostic test (Xpert MTB/RIF) to detect TB among people living with HIV (PLHIV) in high-burden settings. Information on the cost-effectiveness of these recommended strategies is crucial for their implementation.

Methods: We conducted a model-based cost-effectiveness analysis comparing 2 algorithms for TB screening and diagnosis at Ethiopian HIV clinics: (1) WHO-recommended symptom screen combined with Xpert for PLHIV with a positive symptom screen and (2) current recommended practice algorithm (CRPA; based on symptom screening, smear microscopy, and clinical TB diagnosis). Our primary outcome was US$ per disability-adjusted life-year (DALY) averted. Secondary outcomes were additional true-positive diagnoses, and false-negative and false-positive diagnoses averted.

Results: Compared with CRPA, combining a WHO-recommended symptom screen with Xpert was highly cost-effective (incremental cost of $5 per DALY averted). Among a cohort of 15 000 PLHIV with a TB prevalence of 6% (900 TB cases), this algorithm detected 8 more true-positive cases than CRPA, and averted 2045 false-positive and 8 false-negative diagnoses compared with CRPA. The WHO-recommended algorithm was marginally costlier ($240 000) than CRPA ($239 000). In sensitivity analysis, the symptom screen/Xpert algorithm was dominated at low Xpert sensitivity (66%).

Conclusions: In this model-based analysis, combining a WHO-recommended symptom screen with Xpert for TB diagnosis among PLHIV was highly cost-effective ($5 per DALY averted) and more sensitive than CRPA in a high-burden, resource-limited setting.

Citing Articles

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.

Tomeny E, Hampton T, Tran P, Rosu L, Phiri M, Haigh K Pharmacoeconomics. 2024; 42(11):1209-1236.

PMID: 39110388 PMC: 11499453. DOI: 10.1007/s40273-024-01410-x.

Cost-effectiveness of TB diagnostic technologies in Ethiopia: a modelling study.

Assebe L, Erena A, Fikadu L, Alemu B, Baruda Y, Jiao B Cost Eff Resour Alloc. 2024; 22(1):43.

PMID: 38773636 PMC: 11106958. DOI: 10.1186/s12962-024-00544-1.

Efficiency of TB service provision in the public and private health sectors in Ethiopia.

Minwyelet Terefe M, Eyob H, Letta T, Nadew E, Assefa T, Hailu B Int J Tuberc Lung Dis. 2022; 26(12):1128-1136.

PMID: 36447315 PMC: 9728951. DOI: 10.5588/ijtld.21.0481.

Factors influencing the implementation of TB screening among PLHIV in selected HIV clinics in Ghana: a qualitative study.

Narh-Bana S, Kawonga M, Odopey S, Bonsu F, Ibisomi L, Chirwa T BMC Health Serv Res. 2022; 22(1):898.

PMID: 35818070 PMC: 9272598. DOI: 10.1186/s12913-022-08295-6.

A systematic review of scope and quality of health economic evaluations conducted in Ethiopia.

Erku D, Mersha A, Ali E, Gebretekle G, Wubishet B, Kassie G Health Policy Plan. 2022; 37(4):514-522.

PMID: 35266523 PMC: 9128743. DOI: 10.1093/heapol/czac005.

References

Seung K, Omatayo D, Keshavjee S, Furin J, Farmer P, Satti H . Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009; 4(9):e7186. PMC: 2746313. DOI: 10.1371/journal.pone.0007186. View

Tadesse M, Aragaw D, Dimah B, Efa F, Abebe G . Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. Int J Mycobacteriol. 2017; 5 Suppl 1:S48-S49. DOI: 10.1016/j.ijmyco.2016.09.002. View

Balcha T, Sturegard E, Winqvist N, Skogmar S, Reepalu A, Habtamu Jemal Z . Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture. PLoS One. 2014; 9(1):e85478. PMC: 3899028. DOI: 10.1371/journal.pone.0085478. View

Lawn S, Mwaba P, Bates M, Piatek A, Alexander H, Marais B . Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013; 13(4):349-61. PMC: 4844338. DOI: 10.1016/S1473-3099(13)70008-2. View

Boehme C, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F . Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363(11):1005-15. PMC: 2947799. DOI: 10.1056/NEJMoa0907847. View

Adelman M, Tsegaye M, Kempker R, Alebachew T, Haile K, Tesfaye A . Intensified tuberculosis case finding among HIV-infected persons using a WHO symptom screen and Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015; 19(10):1197-203. PMC: 4674437. DOI: 10.5588/ijtld.15.0230. View

Mann G, Squire S, Bissell K, Eliseev P, Du Toit E, Hesseling A . Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis. 2010; 14(12):1518-24. View

Andrews J, Lawn S, Rusu C, Wood R, Noubary F, Bender M . The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012; 26(8):987-95. PMC: 3517815. DOI: 10.1097/QAD.0b013e3283522d47. View

Shah M, Dowdy D, Joloba M, Ssengooba W, Manabe Y, Ellner J . Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. AIDS. 2014; 27(18):2883-92. PMC: 4133735. DOI: 10.1097/QAD.0000000000000008. View

10.

Nakiyingi L, Bwanika J, Kirenga B, Nakanjako D, Katabira C, Lubega G . Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS One. 2013; 8(9):e74023. PMC: 3765314. DOI: 10.1371/journal.pone.0074023. View

11.

Shah S, Demissie M, Lambert L, Ahmed J, Leulseged S, Kebede T . Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2009; 50(5):537-45. DOI: 10.1097/QAI.0b013e318196761c. View

12.

Salomon J, Vos T, Hogan D, Gagnon M, Naghavi M, Mokdad A . Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2129-43. PMC: 10782811. DOI: 10.1016/S0140-6736(12)61680-8. View

13.

Lawn S, Nicol M . Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011; 6(9):1067-82. PMC: 3252681. DOI: 10.2217/fmb.11.84. View

14.

Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S . Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis. 2013; 13:507. PMC: 3833313. DOI: 10.1186/1471-2334-13-507. View

15.

Abebe G, Deribew A, Apers L, Abdissa A, Kiflie Y, Koole O . Evaluation of the 2007 WHO guideline to diagnose smear negative tuberculosis in an urban hospital in Ethiopia. BMC Infect Dis. 2013; 13:427. PMC: 3849989. DOI: 10.1186/1471-2334-13-427. View

16.

Steingart K, Schiller I, Horne D, Pai M, Boehme C, Dendukuri N . Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; (1):CD009593. PMC: 4470349. DOI: 10.1002/14651858.CD009593.pub3. View

17.

Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M . Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013; 383(9915):424-35. DOI: 10.1016/S0140-6736(13)62073-5. View

18.

Floyd K, Fitzpatrick C, Pantoja A, Raviglione M . Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002-11, and requirements to meet 2015 targets. Lancet Glob Health. 2014; 1(2):e105-e115. DOI: 10.1016/S2214-109X(13)70032-9. View

19.

Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W . Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS. 2014; 28(10):1463-72. PMC: 5116236. DOI: 10.1097/QAD.0000000000000278. View

20.

Lawn S, Brooks S, Kranzer K, Nicol M, Whitelaw A, Vogt M . Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011; 8(7):e1001067. PMC: 3144215. DOI: 10.1371/journal.pmed.1001067. View